United Therapeutics Co. (NASDAQ:UTHR) Director Tommy G. Thompson Sells 2,500 Shares of Stock

United Therapeutics Co. (NASDAQ:UTHR) Director Tommy G. Thompson sold 2,500 shares of the company’s stock in a transaction that occurred on Monday, March 24th. The shares were sold at an average price of $318.80, for a total transaction of $797,000.00. Following the completion of the sale, the director now directly owns 8,480 shares of the company’s stock, valued at $2,703,424. The trade was a 22.77 % decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this link.

United Therapeutics Stock Down 1.0 %

Shares of UTHR stock opened at $316.73 on Wednesday. The firm has a market cap of $14.22 billion, a PE ratio of 13.91, a P/E/G ratio of 0.97 and a beta of 0.64. United Therapeutics Co. has a 12 month low of $221.53 and a 12 month high of $417.82. The company’s fifty day simple moving average is $343.28 and its 200-day simple moving average is $356.63.

United Therapeutics (NASDAQ:UTHR) last posted its quarterly earnings data on Wednesday, February 26th. The biotechnology company reported $6.19 EPS for the quarter, topping analysts’ consensus estimates of $6.10 by $0.09. The company had revenue of $735.90 million during the quarter, compared to the consensus estimate of $734.74 million. United Therapeutics had a net margin of 40.31% and a return on equity of 19.22%. During the same period in the prior year, the business posted $4.36 EPS. On average, equities analysts predict that United Therapeutics Co. will post 24.48 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

UTHR has been the subject of a number of recent analyst reports. StockNews.com cut shares of United Therapeutics from a “strong-buy” rating to a “buy” rating in a research report on Thursday, February 27th. HC Wainwright reaffirmed a “buy” rating and set a $425.00 price target on shares of United Therapeutics in a research report on Thursday, February 27th. Finally, UBS Group lifted their price objective on United Therapeutics from $415.00 to $475.00 and gave the company a “buy” rating in a report on Wednesday, January 8th. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating and ten have assigned a buy rating to the company. According to data from MarketBeat.com, United Therapeutics has an average rating of “Moderate Buy” and an average target price of $388.25.

Institutional Inflows and Outflows

A number of hedge funds have recently bought and sold shares of the stock. Milestone Asset Management LLC boosted its holdings in shares of United Therapeutics by 56.5% in the 4th quarter. Milestone Asset Management LLC now owns 2,874 shares of the biotechnology company’s stock valued at $1,014,000 after buying an additional 1,037 shares during the last quarter. Janney Montgomery Scott LLC raised its position in United Therapeutics by 9.1% during the fourth quarter. Janney Montgomery Scott LLC now owns 9,427 shares of the biotechnology company’s stock worth $3,326,000 after acquiring an additional 789 shares in the last quarter. JPMorgan Chase & Co. lifted its stake in United Therapeutics by 35.4% in the third quarter. JPMorgan Chase & Co. now owns 192,546 shares of the biotechnology company’s stock valued at $68,999,000 after acquiring an additional 50,291 shares during the last quarter. Burney Co. lifted its stake in United Therapeutics by 113.3% in the fourth quarter. Burney Co. now owns 23,922 shares of the biotechnology company’s stock valued at $8,441,000 after acquiring an additional 12,705 shares during the last quarter. Finally, Franklin Resources Inc. grew its position in shares of United Therapeutics by 97.7% in the 3rd quarter. Franklin Resources Inc. now owns 250,719 shares of the biotechnology company’s stock valued at $89,532,000 after acquiring an additional 123,929 shares during the period. 94.08% of the stock is currently owned by institutional investors.

United Therapeutics Company Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.